Novo Nordisk nails another phase III study of once-weekly insulin

Results from a late-stage study of insulin icodec show that type 2 diabetes patients were better off on the Danish drugmaker’s experimental drug combined with an app solution than with standard treatment.

Photo: Mads Claus Rasmussen//

On Monday, Novo Nordisk announced a success, reporting positive top-line results for a phase IIIa trial of once-weekly insulin icodec in a company press release.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs